2021 kicks off with positive developments for Dignitana AB
The new year is off to a positive start for Dignitana AB and the company today is providing an update on key actions that will support its accelerated growth -- CPT codes that provide a pathway to reimbursement in the U.S. and clinical guidelines recommending scalp cooling from leading oncology organizations around the world.
Dignitana announced on 30 October 2020 that the American Medical Association (AMA) would issue CPT® Category III codes for mechanical scalp cooling which will take effect 1 July 2021. This week the AMA posted the specific CPT codes for the DigniCap Scalp Cooling System:
- 0662T -- Scalp cooling, mechanical; initial measurement and calibration of cap (once per chemotherapy treatment period)
- 0663T -- Placement of scalp cooling device, monitoring, and removal (once per chemotherapy session)
The availability of CPT codes provides a pathway to insurance reimbursement that will then increase patient access to scalp cooling treatments.
In the fourth quarter the European Society for Medical Oncology (ESMO) updated their Clinical Practice Guidelines to include the recommendation of scalp cooling for the prevention of chemotherapy-induced alopecia as a Category IIB treatment recommendation. A multidisciplinary group of oncology experts from Europe, the United States and Australia authored the recommendation. The ESMO recommendation is similar to those published by Cancer Australia earlier this fall in the Guidance for the management of early breast cancer patients. Additionally, in United States the National Comprehensive Cancer Network® (NCCN) added scalp cooling to their annual guidelines as a Class 2A recommendation for patients with breast cancer in 2019 and ovarian cancer in 2020. These guidelines are widely recognized as the benchmark for oncology treatment coverage and reimbursement by clinicians and payers.
“As we enter the new year we have incredible opportunities ahead of us around the globe. The introduction of CPT codes this year will remove financial barriers in the U.S. and allow us to help more patients. In addition the recommendations from ESMO, Cancer Australia and NCCN are meaningful endorsements of our scalp cooling therapy to the medical community. We value their support as we continue with our plan of accelerated growth,” said William Cronin, Dignitana CEO.
For More Information Contact
Melissa Bourestom, VP Corporate Communications email@example.com +1 469-518-5031
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB +46 8 121 576 90, firstname.lastname@example.org. Learn more at www.dignitana.se or www.dignicap.com.